Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Allergy Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Allergy Other
    Oralair Grasses Approved for Adults With Allergic Rhinoconjunctivitis in Germany - (DGNews)
    Cockroach Immunotherapy Effective in Patients With Allergic Rhinitis, Asthma: Presented at EAACI - (DGDispatch)
    Subcutaneous and Sublingual Therapies Equally Effective in Treating Tree- and Grass-Pollen-Related Rhinoconjunctivitis: Presented at EAACI - (DGDispatch)
    Sublingual Tablets Provide Effective and Safe Immunotherapy for Grass Pollen Allergy: Presented at EAACI - (DGDispatch)
    Sublingual Immunotherapy With Aqueous Vaccine Controls Allergic Diseases: Presented at EAACI - (DGDispatch)

    News archive

     Recent webcasts/CME - Allergy Other
    • Improving Outcomes for Patients With Allergic Rhinitis: An Update From Philadelphia
    • Safety and Efficacy of Novel Agents in Allergic Rhinitis: An Update From AAAAI
    • Understanding the Impact of Allergic Rhinitis on Quality of Life
    • Food Allergies: When the Food Comes to Bite the Gut
      Allergic Rhinitis in Adults and Children

      Webcasts/CME archive

       Recent cases - Allergy Other
        Glucocorticoid Hypersensitivity as a Rare but Potentially Fatal Side Effect of Paediatric Asthma Treatment: A Case Report
        Food-Dependent Exercise-Induced Anaphylaxis Induced by Low Dose Aspirin Therapy
        Allergic Hemiglossitis as a Unique Case of Food Allergy : A Case Report
        Severe Generalised Hypersensitivity Reaction to Topical Neomycin After Cataract Surgery: A Case Report
        Cellphone Contact Dermatitis with Nickel Allergy

        Cases archive
          




        my personal edition > allergy other > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        FDA Approves Olopatadine Nasal Spray for Treatment of Nasal Allergy Symptoms

          HUENENBERG, Switzerland -- April 16, 2008 -- The US Food and Drug Administration (FDA) has approved olopatadine hydrochloride (Patanase) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older.

          FDA approval of olopatadine hydrochloride nasal spray was based primarily on multiple clinical studies for the evaluation of safety, efficacy, and onset of action. The studies were 2-week, randomised, double-blind clinical trials among patients with seasonal allergic rhinitis and were conducted to determine the efficacy of olopatadine in relieving allergy symptoms based on the total nasal symptom score (TNSS). The studies found that patients treated with olopatadine nasal spray -- 2 sprays per nostril twice daily -- demonstrated significantly greater decreases in TNSS compared with the placebo nasal spray.

          Additionally, onset of action was evaluated in 3 environmental exposure unit studies. In these studies, patients with seasonal allergic rhinitis were exposed to high levels of pollen and then were treated with either olopatadine or placebo nasal spray -- 2 sprays in each nostril -- after which they self-reported their allergy symptoms hourly for the subsequent 12 hours. According to these patient reports, olopatadine nasal spray was found to have an onset of action of 30 minutes and a 12-hour duration of effect after dosing, which was statistically significant compared with the placebo spray.

          "For patients who suffer every allergy season with symptoms that make life in those months miserable, [olopatadine] offers relief beginning in minutes in a convenient steroid-free nasal spray," said Eli Meltzer, MD, Co-Director, Allergy and Asthma Medical Group and Research Center, San Diego, California, and lead investigator on one study submitted to the FDA. "The fact that it works quickly is important. Patients in our fast-paced society want rapid improvement and relief from their nasal allergies."


          SOURCE: Alcon, Inc.




        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send